Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection.

In addition, we quantified anti-nucleocapsid antibodies using the Elecsys® Anti-SARS-CoV-2 N kit observing that individuals vaccinated with CoronaVac showed some anti-N antibodies as previously reported,[6] while levels were higher in those previously infected with SARS-CoV-2 (Figure 1C). Keywords: COVID-19: vaccination; SARS-CoV-2; CoronaVac; BNT162b2; anti-RBD kit EN COVID-19: vaccination SARS-CoV-2 CoronaVac BNT162b2 anti-RBD kit 1 3 3 06/08/22 20220401 NES 220401 Humoral immune response through neutralizing antibodies (NAbs) elicited by natural infection or vaccination has been shown as critical in the outcome of COVID-19.[1],[2] NAbs titers vary between different vaccine platforms, and recent findings suggest that individuals with prior SARS-CoV-2 infection receiving viral vector or mRNA vaccines (hybrid immunity) elicit higher titers of NAbs when compared with naïve vaccinees.[3],[4] The aim of study was to compare NAb response to both vaccines in health care workers with and without prior SARS-CoV-2 infection. [Extracted from the article]